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Abstract: Recent advances in next generation sequencing (NGS) and molecular subtyping of tumors have
opened the door to clinically available targeted therapies. Although the treatment of many solid tumors
still rely on a steady regimen of non-targeted chemotherapeutic agents, it is becoming increasingly more
apparent that certain tumors with defects in DNA damage repair (DDR) genes may be exquisitely sensitive
to DNA damaging agents or therapies targeting key elements of this pathway such PARP1, ATR, or ATM.
Still, for tumors with DDR defects the challenges are multi-fold including: (I) identifying these tumors in
patients in time for a window of opportunity of treatment; (II) ensuring that these tumors are still reliant or
addicted to this pathway; and (III) making sure these tumors are matched with the precise treatment option.
Herein, we will discuss the opportunities, challenges, and future of targeting a subset of DDR-defective
tumors.
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Background on the discovery, cloning, and
importance of genome maintenance and DNA
repair genes
Linking BRCA1/2 to cancer predisposition: Let the games
begin
In the early 1990s, BRCA1 was mapped to chromosome
17 (1), and thus, initiated the international effort to link
half the families from a consortium with breast and ovarian
cancers (an inherited predisposition) to this loci (2).
This investigation, amongst others, pioneered the efforts
to discover inherited germline mutations in genes that
could explain the reason why some families had a strong
predisposition to certain tumors. For instance, it is
well established that individuals who carry a germline
heterozygous BRCA1 (or BRCA2) mutation can have a
lifetime risk of ~85% of developing breast and ovarian
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cancers (3), and a higher incidence of developing pancreatic
and prostate cancers than the general population. These
genetic linkage studies were not only enlightening for
genetic testing and identifying cancer predisposition
syndromes, which have highlighted the importance of DNA
repair for cancer prevention (4), but also opened the field
to a new understanding about the intersection between a
defective DDR pathway and tumorigenesis. Finally, the
culmination of this work plus the sequencing of thousands
of cancer genomes have underscored the importance of the
DDR pathway. For instance, to date the clinical concept of
personalizing therapy for the treatment of DDR defective
tumors is very much in vogue.
Although BRCA1/2 have been implicated in a number
of cellular functions, the fact that these genes are
mutated with a high frequency in tumors and have a well
described genome maintenance and repair mechanism,

Ann Pancreat Cancer 2020;3:6 | http://dx.doi.org/10.21037/apc.2020.03.02

Page 2 of 9

has led the field to focus on its role in tumorigenesis (5).
Specifically, BRCA1/2 have been established to play a
key role in collapsed replication forks and double strand
DNA break (DSBs) via homologous recombination (HR),
where the damaged site in DNA sequenced is repaired
in a conventional manner. In a deficient BRCA1/2
setting, cells use a faulty, alternative repair mechanism,
and this is believed to facilitate genetic instability and
tumorigenesis (6).
From genes to an homologous recombination deficiency
(HRD) signature/scar: are all DDR genes mutated equally?
The discovery of DDR genes linked to cancer
predisposition and tumorigenesis has forced NGS panels to
expand personalized approaches to think beyond BRCAness
(i.e., BRCA1/2 genes). However, there are limitations to
just trying to expand the panel of DDR genes. First, it is
unclear whether low frequency mutated DDR genes (or
even variants) are truly driver alterations of tumorigenesis.
Unfortunately, in many instances, including BRCA1/2
mutated tumors, the frequency of mutations found in a
specific tumor type, may be very low compared to more
garden variety cancer driving genes (e.g., Kras or TP53),
making it hard to decipher whether these events are
frequently selected for in a given patient cohort. Based on
the central dogma of conventional cancer genetics, one
must have a mutation frequency in a tumor type which is
greater than expected in a cohort of healthy controls (7).
Other layers of complexity include whether these DDRrelated genes will have the same Achilles Heel (also known
as synthetic lethality) that established DDR genes such as
BRCA1/2 have and whether these genes fit the classical
tumor suppressor rules of needing to have loss of the second
allele in the tumor (e.g., Loss of Heterozygosity, LOH) (7).
Therefore, in many DDR genes, it is unclear whether these
DDR defective genes have predictive therapeutic value.
Based on these concerns, many investigators have attempted
to design assays that detect a molecular signature that could
identify tumors with a defective DDR pathway (i.e., HRD,
see below section).
Specifically, a number of additional genes have been
implicated beyond BRCA1/2 genes in the HR pathway. It
should be noted that these mutations can be categorized
and identified as either germline (i.e., constitutional DNA,
identified in the normal blood or presumable inherited)
or somatic (i.e., found in the tumor DNA, but not in the
germline DNA) in nature. As the field rapidly moves into
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the next versions of NGS, many of these early concepts or
the central dogma of cancer genetics sometimes gets lost in
the commercialization of personalized medicine. The gold
standard for identifying an actionable tumor suppressor
or genome maintenance gene mutation, in this instance
would be a germline mutation (i.e., that causes an amino
acid change) combined with a second, somatic hit mutation
in the other allele, typically via an LOH event. Additional
considerations include identifying whether a somatic
change is authentic based on the availability to obtain pure
DNA from the tumor (without contaminating normal cells
that can confound sequencing results) and matched normal
tissue in order to compare with tumor sequencing results.
An additional level of complexity on determining whether
these HR-gene mutations are authentic, is the fact that
many are considered Variants of Unknown Significance
(VUSs). Many VUSs have been uncharacterized and even
with the confirmation of a potential second allele hit, the
functional significance of these VUSs may either be linked
to a non-driving Single Nucleotide Polymorphism (SNP)
or a more prevalent previously described mutation from a
patient cohort.
With that written, still a number of DDR-HR related
genes have been well described and established. In a recent
publication focused on Homologous Repair-DDR genes
looking at over 52,000 tumors of different origins (e.g.,
biliary tract, GI stromal, bladder, etc.) were analyzed to
identify pathogenic mutations in the HR-DDR genes
including BRCA1/2, BRIP1, RAD50, RAD51, RAD51B,
ATM, ATRX, BARD1, CHEK1/2, FANCA/C/D2/E/F/G/L,
MRE11A, NBN, and PALB2 (8). In this study, they found
that the overall frequency of these mutations were over
17% across 21 tumor lineages. Other studies have focused
on specific lineages, such as a recent study by Pancreatic
Cancer Action Network with the Know Your Tumor
program finding that sequencing data from a cohort of over
600 pancreatic cancers with attempted profiling across 44
states showed a frequency of over 8% mutations in DDR
genes (9). Although these data do not account for the
possibility of the complete loss of the gene, they do support,
similar to other large sequencing studies (10,11), that the
DDR pathway is critically important in the tumorigenesis
process for a number of tumor systems. More recently,
Jonsson et al screened over 17,000 tumor profiles across
55 different types of tumors and found the prevalence
of 2.7% for BRCA1/2 pathologic germline variants (12).
An additional small percentage had somatic mutations.
Combing both germline pathogenic and somatic BRCA1/2
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mutations accounted for 4.9% and covered at least 38 cancer
types of which the majority were pancreatic, breast, ovary,
and prostate cancers (12). Interestingly, only 61% of all
BRCA1/2 carriers with various cancers harbored a somatic
LOH hit in the wild-type BRCA1/2 allele, this number was
significantly enriched over the background rate of LOH
in tumors with non-pathogenic variants (20%) (12). These
data support the notion that in some instances cancers arise
in a setting of BRCA1/2 germline mutations independent
of complete loss of BRCAness. Mouse modeling of these
gene defects support and also refute some of these findings
for the development of cancer. For instance, Venkitaraman
and colleagues (13) generated a murine model of familial
pancreatic cancer (driven by a KRAS G12D mutation) and
found that germline heterozygosity for a functional BRCA2
truncation induced pancreatic ductal adenocarcinomas
(PDACs). Not following the two-hit paradigm, tumor cells
from these animals did not lose a second BRCA2 allele.
Complementary to this work, in three out of four PDACs
from patients who inherited a classic BRCA2999del5
mutation, did not obtain a LOH hit in the second allele (11).
A more recent publication demonstrated two out of three
PDX models from three glBRCA PDAC patients, obtained
LOH in second allele (14). It may depend when the model
systems are developed in relation to the progress of the
patient’s clinical course, since we have shown that over the
course of the disease the patients can develop therapeutic
resistance, thus changing these genomic events (15). Taken
together, these studies: (I) point towards the need of a more
comprehensive molecular signature for BRCAness (i.e.,
HRD scoring); (II) an understanding of how germline and
somatic BRCA1/2 mutations interact with different tumor
systems and lineages; and (III) a caution to the field about
completely relying both on the central dogma of tumor
suppressors in regards to genome maintenance genes and
germline testing.
Next generation germline/patient testing: the search for a
comprehensive molecular signature
Initially, identifying patients with a deficiency in the DDR
pathway was solely based on Sanger Sequencing. The
use of bench techniques to study DNA damage were, and
still are, being explored as a simple test to find a defect
in a pathway, without depicting the exact genetic lesion.
For instance, by running a FAND2 monoubiquitination
assay (Western or immunofluorescence), a molecular
lab could determine whether a mutation occurred in the
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relevant Fanconi Anemia pathway, without knowing the
exact gene that is mutated or loss in a cancer (16,17). The
rapid development of molecular and –omic signatures
have been established since the advent of sequencing,
microarray, and proteomic technologies have gotten
more advanced and facile. The repertoire and diversity of
mutational signatures span from “one-off” publications
(i.e., no follow-up or validating study) depicting the
prognostic value of a sampling of gene expression levels
for the prognostic value and predictive value of a specific
therapy. These studies appeared prevalent in the 1990s
and 2000s, as the ability to validate a specific focused gene
signature in independent cohorts were rare, since largescale, multi-institutional registry and biobanking strategies
were inefficient and rare. More recently, the availability
of well-annotated samples, advanced technologies,
and rigorously validated publicly available datasets has
provided researchers with a reality check on their favorite
or novel multi-panel gene signature (18) [for a recent
comprehensive review see (19)].
As expected, due to the volume of cases and the amount
of available resources (both clinical specimens and funding)
the breast and ovarian cancer fields have led the way in
developing a molecular signature for a HRD-score (20).
Previous scores were solely based on: (I) allelic imbalance
in regards to telomeres (21), (II) LOH (22), and (III) large
scale genomic instability (23). Over the last few years,
others have combined a combination of these markers
with advanced technologies and insights to generate HRD
scores with the ultimate goal to find a reliable assay that can
determine whether a tumor genome is HRD, or even how
immune-active these tumors may be (24,25), for the use as a
predictive biomarker (14,20,26,27).
A therapeutic opportunity: an example of translating the
science to the clinic
As mentioned previously there are differing and overlapping
definitions of HRD in cancer. Furthermore, there may
be subtle but clinically meaningful differences of HRD
signatures per cancer subtype (19). A genomic signature
that defines HRD in ovarian cancer may not have the
same clinical relevance in PDAC. For example, the Myriad
HRD score, was not significantly associated with a higher
response rate or prolonged survival in patients treated with
FOLFIRINOX in a small retrospective study (28) (see
Table 1 list of HRD signatures). The actual prevalence of
HRD in PDAC is estimated to be around 10–12% based on
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Table 1 Examples of homologous recombination deficiency (HRD) scores discovered and presented in the literature
Signature/
algorithm name
Myriad’s
MyChoice HRD

Description & features

Reference

Tested in ovarian tumors and 57 cell lines (breast and pancreatic)

(22)

Association between homologous recombination defects and genomic patterns of loss of heterozygosity
(LOH)
The HRD score appears capable of detecting homologous recombination defects
regardless of etiology or mechanism

Single Base
Substitution
Signatures
(SBS3)

Analysis of 7,042 cancers lead to more than 20 distinct mutational signatures

(18)

SBS3 signature observed in breast, ovarian and pancreatic tumors showed association with BRA1/2
mutations
SBS3 is characterized by large deletions (up to 50 bp) with overlapping microhomology at breakpoint
junctions

HRD gene
signature

Based on transcriptional profiling approach to systematically identify common molecular changes
associated with defective HR repair

(29)

Tested on isogenic cell lines established from MCF-10A cells, an immortal human mammary epithelial cell
line of nonmalignant origin, with induced deficiency individually in HR repair
genes: BRCA1, RAD51 and BRIT1 and other
HRD gene signature allows interrogation of the status of HR repair by simultaneously
considering hundreds of genes and thereby allows identification of HR deficiency in a given cellular state
independent of underlying mechanism
Waddell
structural
variations load
subtyping

Based on whole genome sequencing (WGS) and copy number variation (CNV) analysis
of 100 pancreatic ductal adenocarcinomas (PDAC) tumors

(30)

Patterns of chromosomal structural variations/rearrangements classified PDACs into
4 subtypes with potential clinical utility: stable, locally rearranged, scattered and unstable
Genomic instability co-segregated with inactivation of DNA maintenance genes
(BRCA1, BRCA2 or PALB2) and a mutational signature of DNA damage repair deficiency

Double strand
break repair
signature
(DSBR)

Based on whole genome & RNA sequencing on 160 PDAC cases from 154 patients in the discovery cohort (25)
and WGS of 95 samples in the replication cohort
Analyses of mutational signatures based on Alexandrov approach identified 4 PDAC principal subtypes:
(I) an age-related group dominated by signatures 1 and 5, (II) a double-strand break repair (DSBR) group
characterized by signature 3, attributed to deficiencies in homologous recombination repair (HRR) of doublestrand breaks; (III) a mismatch repair (MMR) group characterized by signatures 6, 20, and 26, attributed to
defects in DNA MMR; and (4) a group characterized by signature 8, of unknown etiology
DSBR &MMR subtypes were associated with increased expression of antitumor immunity, including
activation of CD8-positive T lymphocytes and overexpression of regulatory molecules (CTL4), corresponding
to higher frequency of somatic mutations and tumor-specific neoantigens

HRDetect
score

Based on lasso logistic regression model to identify six distinguishing mutational signatures predictive of
BRCA1/BRCA2 deficiency

(31)

Tested in 560 individuals with breast cancer and validated on independent cohorts of breast, ovarian and
pancreatic cancers
Shows high sensitivity (98.7%) in identification of BRCA1/2 deficient tumors
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whole genome sequencing data (25,30). However, additional
efforts to further define subgroups of patients with platinum
sensitivity are still evolving, and may expand this subgroup
further. Based on the definition of HRD by genomic
alterations in DDR pathways (identified from exome
sequencing NGS), Pishvaian and colleagues demonstrated
a superior overall survival benefit when these patients were
exposed to platinum-based chemotherapy. In this study, the
percentage of patients demonstrating genomic alterations in
DDR pathways was approximately 16% (32).
Are all DNA damaging agents equally efficacious? And at
what time point should these therapies be administered?
It is important to differentiate between the different
mechanisms of actions of the chemotherapeutic agents
versus PARP inhibitors and additional, emerging targeted
DDR drugs in development. These considerations may have
a profound clinical impact, since a DDR-deficient tumor
may show sensitivity to a DDR related chemotherapy, but
not to a specific targeted DDR drug in development (e.g.,
PARP inhibitors and ATR inhibitors).
The platinum salts (carboplatinum, cisplatin and
oxaliplatin), generate covalent cross-links between DNA
bases from DNA-damage-inducing chemotherapies. The
cytotoxic effects are determined by the relative amount and
specific structure of DNA adducts (33). Alkylating agents
(e.g., temozolomide) modify DNA bases. Electrophilic
alkyl groups covalently bind to cellular nucleophilic sites,
including bases in DNA, these interactions are responsible
for cytotoxicity (34). Topoisomerases are essential for all
organisms as they prevent DNA and RNA entanglements
and resolve DNA supercoiling during replication and
transcription. Inhibitors of topoisomerase 1 (camptothecin,
topotecan and irinotecan) and topoisomerase 2 (etoposide
and doxorubicin) generate TOP-DNA adducts and DNAstrand breaks. These drugs generate non-productive TOPDNA cleavage complexes before re-ligation occurs (34).
There are clear similarities and differences between the
DNA-damage-inducing chemotherapies, irinotecan and
platinum agents are standard of care treatments in PDAC
and therefore the most explored in this setting.
A more specific approach to targeting the DDR pathway
includes biological therapeutics specifically Poly (ADPRibose) Polymerase (PARP) inhibitors for tumors with
defects in DNA repair. Tumors with compromised ability
to repair double-strand breaks (DSB) by HR, are highly
sensitive to blockage of the repair of DNA single-strand

© Annals of Pancreatic Cancer. All rights reserved.

Page 5 of 9

breaks (SSB), via the specific and targeted inhibition of
PARP. PARP-inhibition causes failure of the repair SSB.
This SSB encountered by the replication fork will cause
stalling of the fork and therefore may result in fork collapse
or the formation of DSB. In the absence of HR functional
proteins (e.g., BRCA 1/2), the replication fork cannot
be restarted and collapses, causing chromatid breaks.
Additional PARP inhibition mechanisms include the
“trapping” of PARP-1 protein on the site of DNA damage.
This also may interfere with replication fork progression.
This approach has demonstrated wide applicability in
BRCA associated ovarian, breast, prostate and pancreatic
cancer. Furthermore, initial efficacy has also been seen
in the treatment of sporadic cancers with additional HR
pathway impairments (35).
As mentioned, the most well described HRD biomarker
in PDAC is germline BRCA1/2 mutations. The global
prevalence of germline BRCA1/2 is around 7% (36). This
subgroup of patients have shown a superior overall survival
(OS) when treated with platinum based chemotherapy in
retrospective studies (37). However, the toxicity profile of
platinum treatment including the accumulating neuropathy
and hematological toxicity is well described and needs to
be considered here (38). PDAC associated with a germline
BRCA1/2 mutation demonstrate efficacy to platinum
treatment. However, the side effects are debilitating and
dose reductions or cessations are usually mandatory, thus
limiting the profound therapeutic usefulness in BRCAassociated cancers. Therefore, additional maintenance
strategies have been explored. The aim of a maintenance
treatment is to provide an alternative treatment approach
without compromising the patient’s quality of life. The
clinical trial design in maintenance studies, include
comparison of drugs in the maintenance setting that have a
potentially superior therapeutic window. For instance, the
aim of the POLO study: Olaparib as Switch Maintenance
Therapy after Response to platinum-based treatment of
metastatic germline BRCA-mutant (gBRCAm) pancreatic
cancer (36). Patients had to have received a minimum of
16 weeks platinum-based first line chemotherapy, and they
had to demonstrate SD or PR or CR in order to be eligible
for the clinical trial. Identified patients were randomized
in a 2:1 ratio olaparib 300 mg twice daily or placebo. The
primary endpoint PFS was 7.4 months on olaparib versus
3.8 months in the placebo arm, HR 0.53 (95% CI:
0.35–0.82; P=0.0038). Interim OS data (at 46% maturity)
showed no difference between arms. Final OS results will
be evaluated at 69% data maturity. No statistical differences

Ann Pancreat Cancer 2020;3:6 | http://dx.doi.org/10.21037/apc.2020.03.02

Page 6 of 9

Annals of Pancreatic Cancer, 2020

Table 2 Opportunities and challenges of targeting DDR in cancer
Key scientific findings

Clinical implications

Challenges

Link of BRCA1/2
mutations to cancer

Prognostic and predictive
biomarker value

Determining the optimized therapeutic regimen; a deep understanding of the
genetics (LOH, haploinsufficiency, etc.)

HRD score

Predictive biomarker value

Determining the correct therapy; pure tumor tissue access/evaluation; validating
aspects of the score; making facile and economical

POLO study

Maintenance therapy
for PDAC patients

Identifying patients upfront for maximum benefits

Link of DNA repair genes
to cancer

Capturing a greater cohort of
patients for target therapies

Validating that these genes have the same predictive value as BRCA1/2;
determine the significance of VUS or mutations with low frequency within a
tumor system

Resistance occurs with
DNA damaging therapies

Patients recur

Need to better understand genetic and non-genetic mechanisms to overcome
resistance

DDR, DNA damage repair; LOH, loss of heterozygosity; HRD, homologous recombination deficiency; PDAC, pancreatic ductal adenocarcinomas;
VUS, variants of unknown significance.

were noted in quality of life measurements between the
olaparib versus placebo arm. Olaparib-arm patients were
more likely to achieve a response to treatment or maintain
disease control; responses were durable lasting a median of
over 2 years. Of note, this strategic approach of first-line
platinum-based chemotherapy followed by maintenance
PARP inhibitor together has an extended PFS benefit to
patients with a germline BRCA1/2 mutations and metastatic
disease. This study is the first Phase III trial to validate a
targeted treatment in a biomarker-selected population of
pancreatic cancer patients, highlighting the importance of
gBRCAm testing in this setting.
Concluding thoughts and future directions
Clearly both the medical oncology community and our
patients diagnosed with cancer are eager to launch into
the arena of personalized/precision oncology. In this era of
facile genomic sequencing of tumor genomes, identifying
defects in DDR genes or finding a relevant HRD score
has provided a shiny glimmer of hope. The concept and
the success of synthetic lethality for these tumors are
real, as clinical trial data keeps emerging that supports
this therapeutic strategy in numerous oncologic settings,
including maintenance therapy. Simply put, this work is
very promising and exciting for a disease like PDAC, where
only 9% of patients live 5 years; we may offer a significant
subset of patients an enhanced quality of life and overall
survival.
Still there are numerous questions and challenges to
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be worked out as we launch into this next generation
of personalized medicine (Table 2). As outlined above,
optimizing a rapid screening platform against pure tumor
cells will be critical as we attempt to take advantage of a
therapeutic window. However, based on recent data, the
central dogma concept that two hits in a tumor suppressor
or genome maintenance gene may have to be reconsidered
in future and ongoing clinical trials in regards to selection
criteria and retrospective analyses. Additional ramifications
for these findings may not only affect the predictive value
of identifying these mutations, but also have diagnostic
implications for family members of patients who harbor the
same germline mutations. Finally, additional genetic and
beyond genomic alterations (e.g., the immune system and
post-transcriptional gene regulation) in these tumor related
to the DNA repair pathway are still being uncovered (25,39).
These molecular lesions and gene regulatory mechanisms
within tumor cells may provide novel targets, biomarkers,
and important insights into innate and acquired resistance
mechanisms for the above described therapies.
Certainly, a key factor in moving this field forward
will be the prospective clinical and molecular analyses of
ongoing clinical trials (Figure 1). The recent advances in the
development and use of patient derived models of cancer
(14,40,41) will provide an invaluable resource to study
drug-target (gene) relationships, understanding resistance
mechanisms, and may also complement personalized medicine
approaches (Figure 1, Table 1). Taken together, we are
optimistic that validated multiplexed next generation platforms
(that include patient derived models) (Figure 1) that can reliably
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Cancer diagnosis

Family history/
counseling

Patient-derived
modeling for
complementary
drug-target studies

Molecular profiling/HRD score
Germline

Somatic
Collect/analyze
retrospective data
for future trials
For 2nd/3rd line Rx if the
patient becomes resistant

Informed clinical
trial/treatment

Figure 1 A vision for a precision therapy strategy for the treatment of HR deficient tumors. HRD, homologous recombination deficiency.

identify DDR-deficient tumors along with optimized, targeted
therapeutic strategies will be a game changer for many lethal
cancers (e.g., PDAC) with a DDR-defect.
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